Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503510 | 1.00 | TLR7 (0.84) | TLR7IL6 | |
| SCHEMBL1145915 | 0.92 | TLR7 (0.84) | TLR7IL6 | |
| SCHEMBL20740720 | 0.91 | TLR7 (1.00) | TLR7IL6 | |
| SCHEMBL26354073 | 0.91 | TLR7 (0.82) | TLR7IL6 | |
| Hydrochloric Acid SCHEMBL1146402 | 0.91 | TLR7 (0.82) | TLR7IL6 | |
| SCHEMBL24247632 | 0.89 | TLR7 (0.82) | TLR7IL6 | |
| SCHEMBL1146578 | 0.89 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL1146437 | 0.88 | TLR7 (0.78) | TLR7IL6 | |
| SCHEMBL29475674 | 0.87 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL1146575 | 0.87 | TLR7 (0.79) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885IL6 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.